Aggregator

Марка защитных решений стала для взломщиков куда важнее оборотов компании.

Goal Is for Faster, Better Treatment Innovation, Drug Therapies
The U.S. Food and Drug Administration is planning to launch a pilot program aimed at advancing real-time clinical trials through the use of artificial intelligence tools and data science. The goal is to accelerate the development of promising new drugs, which often end up slowed down in bottlenecks.

Elon Musk's Lawsuit Threatens a $852B AI Empire
Elon Musk took the stand this week in a lawsuit that could unwind OpenAI's corporate structure, derail its IPO bid and transform the artificial intelligence landscape. The stakes are high for enterprise customers that bet on OpenAI's technology platform.

Federal Charges Target Recruiters, Managers in Scam Centers After Global Takedown
U.S. and international law enforcement agencies dismantled a network of overseas scam centers linked to cryptocurrency investment fraud schemes, officials said Wednesday, arresting at least 276 individuals in a crackdown across the Middle East and Southeast Asia.

Fabrix Security Buy Adds Real-Time Decisioning for Human and Machine Identities
Silverfort's acquisition of Israeli startup Fabrix Security adds AI-driven, real-time access decisioning built on a contextual knowledge graph, aiming to replace static policies and scale identity security for human, machine and agentic identities operating at machine speed.

1秒root、九年无人知——Linux近年最屌提权漏洞

Но органика мужественно пережила Стёртское оледенение.

基因组学先驱 Craig Venter 去世，享年 79 岁。他因在 1990 年代末与人类基因组计划竞争建立一个基因组数据库而闻名，但他的数据库是设想要付费才能访问，因此在科学界并不受欢迎，促使其他科研团队加速公开发布基因组测序结果。2000 年由美国总统克林顿牵手，人类基因组计划和 Venter 创办的 Celera Genomics 公司同意所有人类基因组数据为人类共同财富，不允许专利保护，且对所有研究者公开。

AI红队实战攻防开源书籍，希望您喜欢！

360亮相数字中国

中国版“Mythos”亮相国际顶会：360展示自动化漏洞利用新突破

Цивилизация не доживёт до следующего века? Подробности интервью Дэвида Гросса.

Goal Is for Faster, Better Treatment Innovation, Drug Therapies
The U.S. Food and Drug Administration is planning to launch a pilot program aimed at advancing real-time clinical trials through the use of artificial intelligence tools and data science. The goal is to accelerate the development of promising new drugs, which often end up slowed down in bottlenecks.